|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net of allowance for credit losses | ||||||||||||||||||||
| Financing receivables, net of allowance for credit losses | ||||||||||||||||||||
| Variable consideration receivables, net of allowance for credit losses | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Film assets, net of accumulated amortization | ||||||||||||||||||||
| Property, plant and equipment, net of accumulated depreciation | ||||||||||||||||||||
| Investment in equity securities | ||||||||||||||||||||
| Lease incentives and other assets | ||||||||||||||||||||
| Deferred income tax assets, net of valuation allowance | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets, net of accumulated amortization | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued and other liabilities | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Revolving credit facility borrowings, net of unamortized debt issuance costs | ||||||||||||||||||||
| Convertible notes and other borrowings, net of unamortized discounts and debt issuance costs | ||||||||||||||||||||
| Deferred income tax liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||
| Capital stock common shares — no par value. Authorized — Unlimited number. 54,842,114 issued and outstanding (December 31, 2025 — 53,921,676 issued and outstanding) | ||||||||||||||||||||
| Other equity | ||||||||||||||||||||
| Statutory surplus reserve | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders’ equity attributable to common shareholders | ||||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
